Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma

被引:22
作者
Munoz, Nina M. [1 ]
Minhaj, Adeeb A. [1 ]
Maldonado, Kiersten L. [2 ]
Kingsley, Charles, V [2 ]
Cortes, Andrea C. [1 ]
Taghavi, Houra [2 ]
Polak, Urszula [1 ]
Mitchell, Jennifer M. [3 ]
Ensor, Joe E. [4 ]
Bankson, James A. [2 ]
Rashid, Asif [5 ]
Avritscher, Rony [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Unit 1471,POB 301402, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77230 USA
[4] Houston Methodist Res Inst, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77230 USA
关键词
Hepatocellular carcinoma; Sorafenib; Contrast-enhanced functional imaging; Vascular permeability; Tissue perfusion; TREATMENT RESPONSE; TARGETED THERAPY; MRI; APOPTOSIS; EFFICACY; TRACER; GROWTH; US;
D O I
10.1016/j.mri.2018.11.012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
100231 [临床病理学]; 100902 [航空航天医学];
摘要
Objectives: To compare the accuracy of contrast-enhanced ultrasound (CEUS) and Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the assessment of changes in tissue vascularization as result of sorafenib treatment in a rat model of hepatocellular carcinoma (HCC). Methods: Male Buffalo rats with orthotopic liver tumors treated daily with 7.5 mg/kg sorafenib via oral gavage for 2 weeks (n = 9) were subject to DCE-MRI and CEUS 2 weeks after tumor implantation - right before treatment initiation - and also after treatment completion - right before tumor harvest. Untreated animals (n = 10) were used as control. Tumor tissue sections were stained for hematoxylin-eosin, pimonidazole, and CD34 for quantitative assessment of necrosis, hypoxia, and microvessel density (MVD), respectively. Results: Of all the DCE-MRI parameters that were evaluated, only volume transfer constant (K-tra(ns)) measurements were significantly lower in sorafenib-treated tumors (0.18 vs 0.33 min(-1), p < 0.01), indicating a substantial decrease in vascular permeability caused by the therapy. This reduction was associated with decreased MVD (3.9 vs 10.8% CD34 + cells, p < 0.01), higher tumor necrosis (31.9 vs 21.8%, p < 0.001) and hypoxia (19.7 vs 10.5% pimonidazole binding, p < 0.01). Moreover, statistical analysis demonstrate significant correlation or DCE-MRJ K-trans. with hisropathologic tissue nccrosis {r = - 0,537, p <-0.05) and MVD (r = 0.599, p < 0.05). Interestingly, none of the CEUS measurements were significantly different between the control and treatment groups, and did not show statistical correlation with any of the histopathological parameters assessed (p > 0.05). Conclusions: Sorafenib-induced reduction in vascular permeability in this preclinical model of HCC is detected more accurately through DCE-MRI than CEUS, and DCE-MRI parameters strongly correlate with histopathological changes in tissue vascularization and tissue necrosis.
引用
收藏
页码:156 / 164
页数:9
相关论文
共 42 条
[1]
Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques [J].
Anderson, H ;
Price, P ;
Blomley, M ;
Leach, MO ;
Workman, P .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1085-1093
[2]
[Anonymous], P INT SOC MAG RESON
[3]
A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness [J].
Baur, Alexander D. J. ;
Schwabe, Julia ;
Rogasch, Julian ;
Maxeiner, Andreas ;
Penzkofer, Tobias ;
Stephan, Carsten ;
Rudl, Marc ;
Hamm, Bernd ;
Jung, Ernst-Michael ;
Fischer, Thom .
EUROPEAN RADIOLOGY, 2018, 28 (05) :1949-1960
[4]
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[5]
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models [J].
Chang, Yong S. ;
Adnane, Jalila ;
Trail, Pamela A. ;
Levy, Joan ;
Henderson, Arris ;
Xue, Dahai ;
Bortolon, Elizabeth ;
Ichetovkin, Marina ;
Chen, Charles ;
McNabola, Angela ;
Wilkie, Dean ;
Carter, Christopher A. ;
Taylor, Ian C. A. ;
Lynch, Mark ;
Wilhelm, Scott .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :561-574
[6]
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[7]
In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media [J].
Cyran, Clemens C. ;
Schwarz, Bettina ;
Paprottka, Philipp M. ;
Sourbron, Steven ;
von Einem, Jobst C. ;
Dietrich, Olaf ;
Hinkel, Rabea ;
Clevert, Dirk A. ;
Brun, Christiane J. ;
Reiser, Maximilian F. ;
Nikolaou, Konstantin ;
Wintersperger, Bernd J. .
CANCER IMAGING, 2013, 13 (04) :557-566
[8]
Dynamic Contrast-Enhanced Computed Tomography Imaging Biomarkers Correlated With Immunohistochemistry for Monitoring the Effects of Sorafenib on Experimental Prostate Carcinomas [J].
Cyran, Clemens C. ;
von Einem, Jobst C. ;
Paprottka, Philipp M. ;
Schwarz, Bettina ;
Ingrisch, Michael ;
Dietrich, Olaf ;
Hinkel, Rabea ;
Bruns, Christiane J. ;
Clevert, Dirk A. ;
Eschbach, Ralf ;
Reiser, Maximilian F. ;
Wintersperger, Bernd J. ;
Nikolaou, Konstantin .
INVESTIGATIVE RADIOLOGY, 2012, 47 (01) :49-57
[9]
Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy [J].
Desar, I. M. E. ;
van Herpen, C. M. L. ;
van Laarhoven, H. W. M. ;
Barentsz, J. O. ;
Oyen, W. J. G. ;
van der Graaf, W. T. A. .
CANCER TREATMENT REVIEWS, 2009, 35 (04) :309-321
[10]
Dobrucki LW, 2010, J NUCL MED, V51, p66S, DOI [10.2967/jnumed.110.074963, 10.2967/jnumed.109.074963]